血氨基酸β生物标志物预测了氨基酸阳性和轻度认知障碍的纵向临床进展
Takuya Ataka1, Noriyuki Kimura1, Naoki Kaneko2
1Department of Neurology Faculty of Medicine Oita University Oita Japan.
Alzheimer's & dementia (New York, N. Y.)
|January 3, 2025
概括
血粉样蛋白β (Aβ) 生物标志物准确地预测大脑粉样蛋白沉积和阿尔茨海默病 (AD) 在老年人中轻度认知障碍 (MCI) 的进展. 这种复合生物标志物在社区环境中显示出高的预测准确性.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 老年医学 老年医学
背景情况:
- 之前对血粉样蛋白β (Aβ) 生物标志物的研究集中在临床队列上,社区环境中的准确性尚不清楚.
- 老年人的轻度认知障碍 (MCI) 需要对大脑粉样蛋白沉积和疾病进展进行可靠的预测.
研究的目的:
- 评估血Aβ生物标志物的预测准确性,用于社区住宿MCI患者的大脑粉样蛋白沉积.
- 评估Aβ生物标志物在预测阿尔茨海默病 (AD) 痴呆症临床进展方面的有用性.
主要方法:
- 未来的队列研究 (2015-2019) 随着长达8年的后续认知评估.
- 在65岁以上的患有MCI的成年人中,通过免疫沉质谱分析的血Aβ生物标志物.
- 接收器操作特征 (ROC) 曲线分析用于预测粉样蛋白状况;卡普兰-梅尔曲线用于临床转换为AD痴呆症.
主要成果:
- 血生物标志物与皮质粉样蛋白吸收有显著的相关性 (ρ = 0.667-0.754).
- 复合生物标志物在预测粉样蛋白阳性方面表现出高准确度 (AUC = 0.943).
- 较高的复合生物标志物水平预测了转化为AD痴呆症的风险增加 (HR = 10.74) 和更快的认知衰退.
结论:
- 血Aβ复合生物标志物作为社区MCI队列中粉样蛋白沉积的可靠替代品.
- 这种生物标志物有效预测疾病的进展和转化为AD痴呆症.
- 脂蛋白E ε4状态会影响血Aβ生物标志物水平.
更多相关视频
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.1K
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
10.5K
相关概念视频
01:26Alzheimer's Disease: Overview
311
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
311
01:22Alzheimer's Disease: Treatment
125
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
125
01:30Dementia
63
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
63